Diabetes Type 1 clinical trials at UCSF
22 in progress, 9 open to eligible people
VX-880 in Participants With Type 1 Diabetes
open to eligible people ages 18-65
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
San Francisco, California and other locations
Device Use Reimagined Through Education And Mentorship
open to eligible people ages 13-17
Diabetes technology, such as insulin pumps and continuous glucose monitoring devices, can help improve glucose control for people with type 1 diabetes (T1D), which keeps them at lower risk for diabetes complications, but many Latinx adolescents, who …
San Francisco, California and other locations
Bolus for Meals in a Closed-loop System
open to eligible people ages 13-19
This study aims to evaluate whether the use of an extended bolus will improve glucose control with high-fat high protein meals using a closed-loop system. The new knowledge gained from this study may provide a method to allow for the proper…
San Francisco, California
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
open to eligible people ages 12-35
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin…
San Francisco, California and other locations
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
open to eligible people ages 12-35
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
San Francisco, California and other locations
MiniMed™ 780G System With DS5 CGM in Children
open to eligible people ages 2-6
The purpose of this study is to evaluate the safety of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 pediatric subjects (2-6 years of age) in a home setting.
San Francisco, California and other locations
Commercial or Open Source Closed Loop Impact on Pregnancy Study
open to eligible females ages 18 years and up
The goal of this observational study is to better understand what happens when pregnant people with type 1 diabetes (T1D) use automated insulin delivery (AID) systems. The main questions this study aims to answer are: - What are the maternal and…
San Francisco, California
TrialNet Pathway to Prevention of T1D
open to eligible people ages 2-45
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in…
San Francisco, California and other locations
Type 1 Diabetes Extension Study
open to eligible people ages 8-35
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study …
San Francisco, California and other locations
GNTI-122 in Adults Recently Diagnosed With T1D
Sorry, not yet accepting patients
This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood…
San Francisco, California and other locations
Automated Insulin for Management of Intrapartum Glycemia
Sorry, not yet accepting patients
The goal of this clinical trial is learn if automated insulin delivery (AID) systems can be used for glucose management during labor/delivery for pregnant people with type 1 diabetes (T1D). The main questions this study aims to answer are - What are …
San Francisco, California
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
Sorry, in progress, not accepting new patients
The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with T1D followed by a 2-year safety follow-up.
San Francisco, California and other locations
Fully Closed Loop At Home (FCL@Home)
Sorry, in progress, not accepting new patients
Protocol Overview/Synopsis This study will be conducted at 3 sites, with each site performing a session with up to 6 participants with a lower HbA1c (<8.0%) in one of 3 age categories (26-60, 18-25, or 14-17 years) followed by a session of up to 6…
San Francisco, California and other locations
Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy
Sorry, not yet accepting patients
The goal of this clinical trial is to learn if patients who have brittle type 1 diabetes receiving an islet transplantation will have better control of their sugars if they also receive one of 2 types of immune cells along with the islet transplant. …
Palo Alto, California
Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes
Sorry, in progress, not accepting new patients
The primary objective is to test the hypothesis that co-transplantation of allogeneic PTG with adult pancreatic islets (derived from same deceased donor) in the IM site in people with Type 1 diabetes with functioning kidney and/or liver transplants…
San Francisco, California
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
Sorry, in progress, not accepting new patients
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to…
San Francisco, California and other locations
Siplizumab in T1DM
Sorry, in progress, not accepting new patients
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible…
San Francisco, California and other locations
STOP-T1D Low-Dose (ATG)
Sorry, in progress, not accepting new patients
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
San Francisco, California and other locations
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Sorry, in progress, not accepting new patients
The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are <8 years of age.
San Francisco, California and other locations
Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol
Sorry, in progress, not accepting new patients
The goal of this trial is to gain initial clinical experience regarding the safety and efficacy of treating type I diabetes in people who have received a kidney transplant by transplanting islets into a new transplant site in the stomach…
San Francisco, California
HLA Demographics Study in Adults With Type 1 Diabetes
Sorry, not yet accepting patients
This is a study to evaluate the HLA-DRB1*04:01 genotype in adults that have been diagnosed with type 1 diabetes
San Francisco, California and other locations
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
Sorry, in progress, not accepting new patients
The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.
San Francisco, California and other locations
Our lead scientists for Diabetes Type 1 research studies include Andrew M Posselt, MD, PhD Jenise C Wong, MD, PhD Stephen Gitelman, MD Peter Stock, MD, PhD Nasim Sobhani, MD Laya Ekhlaspour, MD.
Last updated: